Your shopping cart is currently empty

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor, suppressing the growth of T. gondii strains with a TgDHFR IC50 of 1.57 ± 0.11 nM, a hDHFR IC50 of 308 ± 71 nM, and a hDHFR to TgDHFR selectivity ratio of 196.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 2 mg | $68 | In Stock | In Stock | |
| 5 mg | $118 | In Stock | In Stock | |
| 10 mg | $188 | In Stock | In Stock | |
| 25 mg | $353 | In Stock | In Stock | |
| 50 mg | $492 | In Stock | In Stock | |
| 100 mg | $696 | In Stock | In Stock | |
| 200 mg | $938 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $130 | In Stock | In Stock |
| Description | Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor, suppressing the growth of T. gondii strains with a TgDHFR IC50 of 1.57 ± 0.11 nM, a hDHFR IC50 of 308 ± 71 nM, and a hDHFR to TgDHFR selectivity ratio of 196. |
| Targets&IC50 | TgDHFR:1.57 ± 0.11 nM(Toxoplasma gondii), DHFR (human):308 ± 71 nM(human) |
| In vitro | Fanotaprim exhibits parasiticidal and antiproliferative effects with EC50s of 13 and 7300 nM against the type I RH strain of T. gondii and MCF-7 cells, respectively[1]. It also inhibits the growth of T. gondii strains in vitro with EC50s ranging from 7.6 to 29.8 nM (GT1, ME49, CTG, RUB, and VAND)[1]. |
| In vivo | Fanotaprim (1-10 mg/kg; p.o.; daily; beginning on day 1 through day 7) is highly effective in controlling acute infection by highly virulent strains of T. gondii in the murine model[1]. In mice, Fanotaprim (1 mg/kg; i.v.) shows CL, Vd, and t1/2 values of 10.6 mL/min/kg, 1.14 L/kg, and 3.9 hours, respectively[1]. When administered orally at 0.83 mg/kg, Fanotaprim exhibits F, Cmax, Tmax, and AUC0-last values of 47.3%, 178 ng/mL, 0.05 hours, and 750 ng h/mL, respectively[1]. |
| Molecular Weight | 378.43 |
| Formula | C19H22N8O |
| Cas No. | 2120282-75-7 |
| Smiles | COc1ncc(cn1)-c1cccc(c1)N1CCN(CC1)c1cnc(N)nc1N |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (66.06 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.